JBJoerg Buddenkotte

Joerg Buddenkotte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joerg Buddenkotte has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Involvement of B Cell Subsets in Patients With Steven Johnson Syndrome/Toxic Epidermal Necrolysis ( SJS / TEN )

    by Fareed Ahmad, Jericha Miles P. Mateo, Febu Elizabeth Joy, Gazala Anamangadan, Seena Manjooran, Anh Jochebeth, Fahad Al‐Marri, Sara Al‐Khawaga, Amina Al‐Obaidli, Ayda AlHammadi, et al.

  • Basophil activity in atopic dermatitis: Distinct immunomodulatory roles of dupilumab and abrocitinib

    by Wenjing Jiang, Xinyang Xie, Sai Yang, Rui Xu, Jui-Wen Chang, Xiru Tang, Ruixin Yu, Yalin Xie, Wenhui Liu, Rui Tang, et al.

  • Open Access

    Targeting FOXM1 regulates metabolic signatures through ROS-dependent JNK/Bmi1/Skp2 axis in human cutaneous T-cell lymphoma

    by Abdul Q. Khan, Maha Agha, Fareed Ahmad, Rasheeda Anver, Majid Alam, Joerg Buddenkotte, Shahab Uddin, Martin Steinhoff

    Cutaneous T-cell lymphoma (CTCL) is a progressive and heterogeneous malignancy characterized by deregulated metabolic reprogramming and cancer stemness, with limited therapeutic options. Therefore, elucidating the mechanisms driving metabolic reprogramming and poor clinical outcomes in CTCL is imperative. Forkhead box protein M1 (FOXM1), an oncogenic transcription factor, plays a pivotal role in cancer pathogenesis by orchestrating metabolic reprogramming and stemness signaling, thereby contributing to therapeutic resistance. In this study, we investigated the therapeutic potential of FOXM1 inhibition in human CTCL cells. Both genetic and pharmacological targeting of FOXM1 markedly suppressed CTCL cell growth and proliferation by inducing programmed cell death (apoptosis and autophagy) via reactive oxygen species (ROS) generation. Mechanistic analyses revealed that the activation of the MAPK, particularly JNK activation, is crucial for thiostrepton-induced programmed cell death. Metabolomics profiling further demonstrated that thiostrepton treatment triggers ROS- and JNK-dependent alteration in metabolic pathways central to cancer hallmarks, including amino acid and lipid metabolism. Notably, FOXM1 inhibition abrogated stemness-associated metabolic reprogramming genes (KLF-4, Bmi1) and Skp2, while upregulating the tumor suppressor p21 in a JNK-dependent manner. Moreover, thiostrepton treatment sensitized the CTCL cells to proteasome inhibitor bortezomib, promoting apoptosis and autophagy. Collectively, these findings demonstrate that FOXM1 targeting disrupts the metabolic status and stemness features of CTCL cells via JNK activation, thereby offering novel insights into potential therapeutic strategies for overcoming therapeutic challenges in CTCL.


  • The Neurogenic Inflammation Mediator Endothelin‐1 Causes Human Skin Barrier Disruption in Atopic Dermatitis via an ETAR / TRPA1 ‐Axis

    by Rari Leo, Anh Jochebeth, Nabeel Abdulrahman, Maha Victor Agha, Febu Elizabeth Joy, Ayda AlHammadi, Shahad M. Younis, Sara Al‐Harami, Ahmed Al‐Qahtani, Fareed Ahmad, et al.

    Background: Atopic dermatitis (AD) is a common, relapsing inflammatory skin disease driven by an immune imbalance, microbial dysbiosis, and skin barrier impairment, culminating in (neurogenic) inflammation and itch. We hypothesized that the neuropeptide and pruritogen endothelin‐1 (ET‐1) contributes to AD pathology by impeding skin barrier formation via its cognate receptor ETAR and TRPA1, a cation channel involved in neurogenic inflammation, pain, and itch. Methods: We utilized differentiated human keratinocytes and ex vivo human skin organ cultures in vitro to evaluate the impact of ET‐1 on human skin barrier function. ET‐1 effects were assessed at the RNA level by RT‐qPCR and at the protein level by quantitative immunofluorescence microscopy. Barrier integrity was monitored using real‐time cell analysis and transwell permeability assays. Results: ET‐1 markedly reduced cell resistance in differentiated keratinocytes, an effect abrogated by the ETAR antagonist bosentan. ET‐1 significantly decreased expression of skin differentiation markers filaggrin and loricrin, and tight junction proteins occludin, claudin‐1, and claudin‐4, at mRNA and protein levels. ETAR‐specific siRNA in combination with ET‐1, rescued ET‐1‐mediated downregulation of filaggrin. Furthermore, TRPA1 antagonist HC‐030031 abrogated the impairing effect of ET‐1 on the skin barrier. We observed increased inflammatory responses of ET‐1‐stimulated keratinocytes, suggesting that the ET‐1‐initiated barrier disruption could be mediated by IL‐6 and IL‐1β and induced by TNF‐α. Conclusion: Our findings suggest that a neurogenic inflammation axis ET‐1/ETAR/TRPA1 contributes to skin barrier impairment in AD by repressing differentiation markers and tight junction proteins. Additionally, we demonstrate ETAR‐blockage as a rational therapeutic modality for patients with AD.


  • Open Access

    Interleukin-31: The Inflammatory Cytokine Connecting Pruritus and Cancer

    by Sabah Akhtar, Fareed Ahmad, Majid Alam, Abdul Wahid Ansari, Shahab Uddin, Martin Steinhoff, Joerg Buddenkotte, Aamir Ahmad, Angeliki Datsi

    Interleukin 31 (IL-31) is a proinflammatory cytokine, mainly secreted by Type II helper T cells. It signals through a heterodimeric receptor complex composed of IL-31 receptor α and oncostatin-M receptor β chain. The hallmark feature of IL-31, in its pathological role, is its ability to induce pruritus in mammals. Pruritus is a common symptom and major reason of morbidity in cancer patients, compromising their quality of life. Although, IL-31 is differentially expressed in different tumor types and could promote or inhibit cancer progression, high expression of IL-31 is a contributing factor to advanced stage tumor and severity of pruritus. The simultaneous existence of pruritus and cancer could either result from the aberrations in common proteins that co-exist in both cancer and pruritus or the therapeutic treatment of cancer could indirectly induce pruritus. Although the biology of IL-31 has predominantly been described in skin diseases such as atopic dermatitis and other inflammatory diseases, the precise role of IL-31 in the tumor biology of different cancer types remains elusive. Herein, we summarize the current understanding on the role of this cytokine in the pathogenesis of different cancers.


  • Open Access

    Neuronal BST2: A Pruritic Mediator alongside Protease-Activated Receptor 2 in the IL-27–Driven Itch Pathway

    by Yanqing Li, Weiwei Chen, Xingyun Zhu, Huiyuan Mei, Martin Steinhoff, Joerg Buddenkotte, Jinhai Wang, Wenhao Zhang, Zhenghui Li, Xiaolong Dai, et al.


  • Top Cited Papers

    Emerging Role of the IL-36/IL-36R Axis in Multiple Inflammatory Skin Diseases

    by Fareed Ahmad, Majid Ali Alam, Abdul Wahid Ansari, Anh Jochebeth, Rari Leo, Mohammed Nasser Al-Abdulla, Sara Al-Khawaga, Ayda AlHammadi, Aysha Al-Malki, Khalifa Al Naama, et al.


  • Flushing New Light on Rosacea

    by Martin Steinhoff, Joerg Buddenkotte


  • Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis

    by Nabeel Abdulrahman, Rari Leo, Hasna Amal Boumenar, Fareed Ahmad, Jericha M. Mateo, Anh Jochebeth, Naila Khalid Al-Sowaidi, Gulab Sher, Abdul W. Ansari, Majid Alam, et al.

    Cutaneous T cell lymphoma (CTCL) is a varied group of neoplasms that affects the skin. Acquired resistance against chemotherapeutic drugs and associated toxic side effects are limitations that warrant search for novel drugs against CTCL. Embelin (EMB) is a naturally occurring benzoquinone derivative that has gained attention owing to its anticancer pharmacological actions and nontoxic nature. We assessed the anticancer activity of EMB against CTCL cell lines, HuT78, and H9. EMB inhibited viability of CTCL cells in a dose-dependent manner. EMB activated extrinsic and intrinsic pathways of apoptosis as shown by the activation of initiator and executioner caspases. EMB-induced apoptosis also involved suppression of inhibitors of apoptosis, XIAP, cIAP1, and cIAP2. PARP cleavage and upregulation of pH2AX indicated DNA damage induced by EMB. In conclusion, we characterized a novel apoptosis-inducing activity of EMB against CTCL cells, implicating EMB as a potential therapeutic agent against CTCL.


  • Open Access

    The PLAUR signaling promotes chronic pruritus

    by Weiwei Chen, Yanqing Li, Martin Steinhoff, Wenhao Zhang, Joerg Buddenkotte, Timo Buhl, Renkai Zhu, Xinrong Yan, Zhiping Lu, Song Xiao, et al.

    Chronic itch is a complex sensation of the skin frequently associated with skin diseases, such as atopic dermatitis (AD) and psoriasis. Although Serpin E1 is implicated in chronic itch, its receptor and signaling pathways involved in itch are not known. In this study, the clinical relevance of a putative Serpin E1 receptor PLAUR to chronic itch, and the neuro‐cutaneous Serpin E1‐PLAUR signaling are explored. We found that PLAUR is overexpressed in skin specimens of human lesional AD and lesional psoriasis, and sensory neurons innervating MC903‐induced AD‐like murine skin. Murine PLAUR + sensory neurons responded to Serpin E1, resulting in enrichment of numerous itch‐ and inflammation‐related genes and their protein release. PLAUR resides in TLR2 + neurons and Serpin E1 stimulus led to transcriptional upregulation of TLR2 and its co‐signaling proteins. Agonists of TLR2 propagated itch‐related gene transcription including BNP, OSM, and PAR2. OSM induced acute itch in mice and promoted G‐CSF and IL‐8 release from human keratinocytes. Serpin E1 inhibitor reduced MC903‐induced itch, epidermal hyperplasia, immunocyte infiltration, and resulted in lower transcription/expression levels of Serpin E1 and OSM. Taken together, the PLAUR‐TLR2‐OSM signaling promotes skin‐nerve communication, cutaneous inflammation, and itch, all feeding into an aggravation of AD and exaggerated itch circuits.